194 related articles for article (PubMed ID: 15110086)
21. Nontoxic doses of suramin enhance activity of doxorubicin in prostate tumors.
Zhang Y; Song S; Yang F; Au JL; Wientjes MG
J Pharmacol Exp Ther; 2001 Nov; 299(2):426-33. PubMed ID: 11602651
[TBL] [Abstract][Full Text] [Related]
22. Schedule-dependent interaction between Doxorubicin and mTHPC-mediated photodynamic therapy in murine hepatoma in vitro and in vivo.
Kirveliene V; Grazeliene G; Dabkeviciene D; Micke I; Kirvelis D; Juodka B; Didziapetriene J
Cancer Chemother Pharmacol; 2006 Jan; 57(1):65-72. PubMed ID: 16001168
[TBL] [Abstract][Full Text] [Related]
23. In vivo distribution and antitumor activity of heparin-stabilized doxorubicin-loaded liposomes.
Han HD; Lee A; Song CK; Hwang T; Seong H; Lee CO; Shin BC
Int J Pharm; 2006 Apr; 313(1-2):181-8. PubMed ID: 16540270
[TBL] [Abstract][Full Text] [Related]
24. Intracellular doxorubicin kinetics in lymphoma cells and lymphocytes infiltrating the tumor area in vivo: a flow cytometric study.
Zaleskis G; Ho RL; Diegelman P; Maccubbin D; Ujházy P; Mihich E; Ehrke MJ
Oncol Res; 1994; 6(4-5):183-94. PubMed ID: 7841541
[TBL] [Abstract][Full Text] [Related]
25. Effect of dihydrokainate on the antitumor activity of doxorubicin.
Sadzuka Y; Yamashita Y; Sugiyama T; Sonobe T
Cancer Lett; 2002 May; 179(2):157-63. PubMed ID: 11888670
[TBL] [Abstract][Full Text] [Related]
26. Fluoxetine inhibits multidrug resistance extrusion pumps and enhances responses to chemotherapy in syngeneic and in human xenograft mouse tumor models.
Peer D; Dekel Y; Melikhov D; Margalit R
Cancer Res; 2004 Oct; 64(20):7562-9. PubMed ID: 15492283
[TBL] [Abstract][Full Text] [Related]
27. MST-16, a novel bis-dioxopiperazine anticancer agent, ameliorates doxorubicin-induced acute toxicity while maintaining antitumor efficacy.
Yoshida M; Maehara Y; Sugimachi K
Clin Cancer Res; 1999 Dec; 5(12):4295-300. PubMed ID: 10632373
[TBL] [Abstract][Full Text] [Related]
28. Uptake of the anthracycline pirarubicin into mouse M5076 ovarian sarcoma cells via a sodium-dependent nucleoside transport system.
Nagai K; Nagasawa K; Fujimoto S
Cancer Chemother Pharmacol; 2005 Mar; 55(3):222-30. PubMed ID: 15526202
[TBL] [Abstract][Full Text] [Related]
29. Relationships between the in vitro cytotoxicity and transport characteristics of pirarubicin and doxorubicin in M5076 ovarian sarcoma cells, and comparison with those in Ehrlich ascites carcinoma cells.
Nagai K; Nagasawa K; Sadzuka Y; Tsujimoto M; Takara K; Ohnishi N; Yokoyama T; Fujimoto S
Cancer Chemother Pharmacol; 2002 Mar; 49(3):244-50. PubMed ID: 11935217
[TBL] [Abstract][Full Text] [Related]
30. In vivo reversal of doxorubicin resistance by (-)-epigallocatechin gallate in a solid human carcinoma xenograft.
Zhang Q; Wei D; Liu J
Cancer Lett; 2004 May; 208(2):179-86. PubMed ID: 15142676
[TBL] [Abstract][Full Text] [Related]
31. Magnetic resonance imaging of temperature-sensitive liposome release: drug dose painting and antitumor effects.
Ponce AM; Viglianti BL; Yu D; Yarmolenko PS; Michelich CR; Woo J; Bally MB; Dewhirst MW
J Natl Cancer Inst; 2007 Jan; 99(1):53-63. PubMed ID: 17202113
[TBL] [Abstract][Full Text] [Related]
32. Motexafin gadolinium: a redox active drug that enhances the efficacy of bleomycin and doxorubicin.
Miller RA; Woodburn KW; Fan Q; Lee I; Miles D; Duran G; Sikic B; Magda D
Clin Cancer Res; 2001 Oct; 7(10):3215-21. PubMed ID: 11595717
[TBL] [Abstract][Full Text] [Related]
33. Proanthocyanidin from grape seeds enhances doxorubicin-induced antitumor effect and reverses drug resistance in doxorubicin-resistant K562/DOX cells.
Zhang XY; Li WG; Wu YJ; Bai DC; Liu NF
Can J Physiol Pharmacol; 2005 Mar; 83(3):309-18. PubMed ID: 15870845
[TBL] [Abstract][Full Text] [Related]
34. [Synergism of sobuzoxane in combination with doxorubicin against leukemia P388 in mice].
Dai ZQ; Xu JY; Yuan XJ; Cai JC
Zhongguo Yao Li Xue Bao; 1996 Jan; 17(1):69-71. PubMed ID: 8737460
[TBL] [Abstract][Full Text] [Related]
35. Beneficial effects of curcumin on antitumor activity and adverse reactions of doxorubicin.
Sadzuka Y; Nagamine M; Toyooka T; Ibuki Y; Sonobe T
Int J Pharm; 2012 Aug; 432(1-2):42-9. PubMed ID: 22569233
[TBL] [Abstract][Full Text] [Related]
36. Determinants for in vivo anti-tumor effects of PEG liposomal doxorubicin: importance of vascular permeability within tumors.
Ogawara K; Un K; Minato K; Tanaka K; Higaki K; Kimura T
Int J Pharm; 2008 Jul; 359(1-2):234-40. PubMed ID: 18448289
[TBL] [Abstract][Full Text] [Related]
37. Vascular targeting of doxorubicin using cationic liposomes.
Wu J; Lee A; Lu Y; Lee RJ
Int J Pharm; 2007 Jun; 337(1-2):329-35. PubMed ID: 17275230
[TBL] [Abstract][Full Text] [Related]
38. Doxorubicin directs the accumulation of interleukin-12 induced IFN gamma into tumors for enhancing STAT1 dependent antitumor effect.
Zhu S; Waguespack M; Barker SA; Li S
Clin Cancer Res; 2007 Jul; 13(14):4252-60. PubMed ID: 17634555
[TBL] [Abstract][Full Text] [Related]
39. Improvements of doxorubicin-induced antitumor activity and adverse reaction by combined citrulline.
Miyashita M; Sadzuka Y
Biol Pharm Bull; 2014; 37(3):447-53. PubMed ID: 24583863
[TBL] [Abstract][Full Text] [Related]
40. Targeted delivery of doxorubicin using stealth liposomes modified with transferrin.
Li X; Ding L; Xu Y; Wang Y; Ping Q
Int J Pharm; 2009 May; 373(1-2):116-23. PubMed ID: 19429296
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
